News and Trends 28 Jul 2022 Commercial launch of Monkeypox PCR test announced for research A PCR test to pick up the monkeypox virus is now available outside the US for use in research applications by laboratories. Becton, Dickinson and Company (BD) a global medical technology company and CerTesy Biotec made the announcement today (July 27). The BD MAX System used to leverage the test is a fully integrated, automated […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 T-cell therapy company AlloVir set to raise $126.6M AlloVir, Inc., a late clinical-stage allogeneic T-cell immunotherapy company, has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock in a registered direct offering at a purchase price of $4.61 per share. Gross proceeds from the offering will equal approximately $126.6 million. The […] July 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […] July 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 InterVenn expands globally to drive the potential of glycoproteomics to improve patient outcomes Intervenn Biosciences is expanding across Asia-Pacific and North America and opening new facilities in Kuala Lumpur, the Philippines, Australia and California. The company leverages glycoporteomics and says it is adding a large footprint of laboratories and office space for scaling up Intervenn’s software development, technical support, clinical research and business development. Biomedical hubs Aldo Carrascoso, […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Boston startup bags $40M Series A to smash preclinical bottlenecks The U.S. company Manifold Bio has raised $40 million in a Series A round to bankroll protein barcoding technology that could speed up the preclinical development of targeted cancer drugs. Two years after bagging a $5.4 million seed investment, the Boston-based protein drug developer Manifold Bio has hit the headlines with a $40 million round […] July 14, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Jul 2022 Paradigm of treatment of mental health to be transformed by gut-brain development program Building on a decade of research, a development program for next-generation probiotics and therapeutics to modulate gut microbiota and mental health has been launched. Seed Health, a microbiome science company along with Axial Therapeutics, a clinical stage biopharmaceutical company announced the joint program in the US today (July 13). It will build on the work […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 AI being used to perform molecular analysis of biopsies from bowel disease patients Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […] July 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2022 ARCH Venture Partners launches $3B fund for biotech companies ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. The new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI. “All the fundamental innovations in biotechnology are accelerating, with huge promise […] June 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Eye inflammation leads to FDA partial clinical hold on Nuvation Bio solid tumor study U.S. biopharma company Nuvation Bio Inc. says the Food and Drug Administration (FDA) has placed a partial clinical hold on the company’s phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The company’s Phase 1 trial began enrolling patients in […] June 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email